Serum levels of VCAM-1 are associated with survival in patients treated with nivolumab for NSCLC
Autor: | Paolo Spallarossa, Federico Carbone, Francesco Grossi, Marco Tagliamento, Angela Alama, Alessandra Vecchié, Daniele Ferrara, Silvia Minetti, Aldo Bonaventura, Giovanni Rossi, Erika Rijavec, Edoardo Elia, Federico Biello, Simona Coco, Nicholas Bardi, Anna Maria Ansaldo, Maria Giovanna Dal Bello, Fabrizio Montecucco, Carlo Genova, Stefano Ministrini |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
Male
Oncology medicine.medical_specialty Lung Neoplasms medicine.medical_treatment Clinical Biochemistry Antineoplastic Agents Biochemistry chemistry.chemical_compound Antineoplastic Agents Immunological intracellular adhesion molecule-1 Predictive Value of Tests Carcinoma Non-Small-Cell Lung Internal medicine Humans Medicine In patient nivolumab non-small cell lung cancer programmed cell-death protein-1 vascular cell adhesion molecule-1 VCAM-1 Non-Small-Cell Lung Cell adhesion Aged Female Middle Aged Nivolumab Prognosis Survival Rate Vascular Cell Adhesion Molecule-1 business.industry Cell adhesion molecule Carcinoma Confounding General Medicine Immunotherapy Immunological chemistry Non small cell business |
Popis: | Background High circulating levels of cellular adhesion molecules (CAMs) in non-small cell lung cancer (NSCLC) have been supposed to act as a negative prognostic factor. Here, we explored the predictive role of pre-treatment levels of CAMs in previously treated patients receiving nivolumab for NSCLC. Materials and methods Seventy one patients with advanced NSCLC, treated with nivolumab at the dose of 3 mg/kg every 14 days, were enrolled. Maximum follow-up time was 3 years. Serum levels of Vascular Cell Adhesion Molecule-1 (VCAM-1) and Intracellular Adhesion Molecule-1 (ICAM-1) were measured at baseline and before each nivolumab administration. Endpoints of the study were a composite outcome of survival ≥2 years or absence of disease progression at the end of the follow-up, and the overall survival. Results Composite outcome and overall survival were positively associated with VCAM-1 baseline levels and with the reduction of VCAM-1 during the treatment. After adjustment for potential confounders, the change in VCAM-1 serum levels during the treatment was an independent predictor of overall survival. Conclusions High baseline serum levels of VCAM-1 are associated with a longer survival in patients treated with nivolumab as second line treatment for NSCLC. Surviving patients experience also a significant reduction in CAMs expression during the treatment. Hence, CAMs might be promising prognostic factors in patients with NSCLC underoing immunotherapy. |
Databáze: | OpenAIRE |
Externí odkaz: |